Novo Nordisk's Ziltivekimab Fails Phase 3 Cardiovascular Trial

What happened

Novo Nordisk announced topline results from its Phase 3 ZEUS trial evaluating ziltivekimab, a monthly injectable drug targeting the IL-6 inflammatory pathway. The trial enrolled over 6,300 participants with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation markers (high-sensitivity C-reactive protein levels of at least 2 mg/L). While ziltivekimab successfully reduced inflammatory biomarkers including C-reactive protein, fibrinogen, and lipoprotein(a), it failed to meet the primary endpoint of reducing major adverse cardiovascular events (MACE) - cardiovascular death, nonfatal heart attack, or nonfatal stroke. The hazard ratio was 0.99 (95% CI: 0.88-1.11), indicating no statistical benefit versus placebo. Additionally, a higher proportion of patients receiving ziltivekimab experienced serious infections compared to placebo, though overall mortality rates were similar between groups.

Why it matters

This clinical failure represents a significant setback to Novo Nordisk's strategy to diversify revenue streams beyond its blockbuster GLP-1 diabetes and obesity drugs (Ozempic and Wegovy). Ziltivekimab was the company's primary candidate to establish a presence in non-obesity cardiovascular medicine, a large unmet medical need. The drug's inability to translate anti-inflammatory effects into measurable cardiovascular benefits raises questions about the IL-6 inhibition approach for this patient population. Novo Nordisk will record a non-cash impairment charge in Q3 2025, though the company stated the failure won't affect its adjusted operating profit outlook for 2026. The trial outcome also raises concerns about two ongoing ziltivekimab trials - HERMES (heart failure patients) and ARTEMIS (acute heart attack patients) - which are expected to report results in the first half of 2027.

Bigger picture

The failure underscores the challenge pharmaceutical companies face in developing effective cardiovascular therapies beyond traditional approaches like statins and blood pressure medications. Targeting inflammation has been a promising but elusive strategy in cardiovascular disease prevention. For Novo Nordisk, the setback comes at a time when the company faces intensifying competition in the GLP-1 market, particularly from Eli Lilly's tirzepatide. Novo Nordisk's next-generation obesity drug CagriSema recently underperformed against Lilly's treatment in head-to-head trials. Despite these challenges, the broader GLP-1 obesity treatment market is projected to reach $120 billion by 2030, and Novo Nordisk recently raised its full-year guidance based on strong Wegovy sales. The company's shares now trade at a forward P/E ratio of approximately 15x, significantly below rival Eli Lilly's 35x multiple, and near historical lows around 11x trailing P/E.

What to watch

Investors should monitor Novo Nordisk's Q2 earnings release scheduled for August 5, 2025, where consensus estimates call for $0.81 earnings per share, representing a 16.5% decline year-over-year. The company's decision on whether to continue development of ziltivekimab in the HERMES and ARTEMIS trials will be critical, with those results expected in early 2027. Full ZEUS trial data will be presented at a scientific meeting in 2026, providing deeper insight into why inflammatory marker reduction didn't translate to cardiovascular benefits. Additionally, ongoing competitive dynamics in the GLP-1 market and Novo Nordisk's pipeline progress in obesity and diabetes treatments will remain key focus areas. The company currently offers a 3.84% dividend yield, which may provide some downside protection as investors reassess the stock's long-term growth prospects.